Time to read
1 minute
Read so far

Colon surgery often sufficient to avoid recurrence in cancer patients

Thu, 08/30/2018 - 16:42
Posted in:

Many patients with colon cancer do not need any chemotherapy and in those patients who benefit from chemotherapy it does not have to be as intense for everyone, according to a new study from Uppsala University.

Colon cancer is usually treated with surgery but to reduce the risk for recurrence chemotherapy is also administered in some cases. Thanks to an improved care in later years the recurrence risk has decreased, which can affect the benefit of giving chemotherapy that is often accompanied by harmful adverse effects.

In a recent study, ‘Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology,’ published in the journal Diseases of the Colon and Rectum - from the Department of Immunology, Genetics and Pathology at Uppsala University – Drs Erik Osterman and Bengt Glimelius analysed data from all Swedish patients that underwent surgery for colon cancer in the years 2007–2012 to determine whether it, given today's treatment and care, is justified to administer chemotherapy to reduce recurrence risk.

"We analysed data from more than 14,000 patients and saw that the recurrence risk after surgery was five per cent in the least advanced stage, twelve per cent in more deep tumours, i.e. stage II, and thirty-three per cent when there were lymph node metastases, that is stage III,” explained Dr Erik Osterman. “These rates are lower than those seen in historical material, which current treatment guidelines are based on."

The five-year recurrence rate was 5% in stage I, 12% in stage II, and 33% in stage III patients. In patients classified as having pT3N0 cancer with no or one risk factor, the five-year recurrence rates were 9% and 11%. Risk factors for shorter time to recurrence were male sex, more advanced pT and pN classification, vascular and perineural invasion, emergency surgery, lack of central ligature, short longitudinal resection margin, postoperative complications, and, in stage III, no adjuvant chemotherapy.

Based on these rates the researchers could estimate that for many patients in stage II, chemotherapy in combination with surgery would mean that two recurrences could be avoided per one hundred treated patients. For many stage III patients, they found that four to five recurrences per hundred treated patients could be avoided with one chemotherapy agent, and an additional three per hundred treated using two chemotherapy agents.

"These gains can be considered too small compared with the risk for adverse effects to justify chemotherapy for low-risk patients in stage II. It is also not justified to give a double treatment to low-risk patients in stage III,” added Dr Erik Osterman. “Our conclusion is that tumour classification and risk factors can enable the identification of large patient groups characterised by such a low recurrence rate that it is questionable whether chemotherapy in motivated.”